News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
2,837 Results
Type
Article (450)
Company Profile (1)
Press Release (2386)
Multimedia
Podcasts (4)
Webinars (2)
Section
Business (1012)
Career Advice (4)
Deals (110)
Drug Delivery (1)
Drug Development (632)
Employer Resources (6)
FDA (62)
Job Trends (145)
News (1722)
Policy (150)
Tag
Academia (4)
Alliances (227)
ALS (1)
Alzheimer's disease (13)
Approvals (62)
Artificial intelligence (3)
Autoimmune disease (1)
Bankruptcy (1)
Best Places to Work (135)
Biotechnology (1)
Breast cancer (1)
Cancer (4)
Cardiovascular disease (32)
Career advice (5)
CDC (1)
Cell therapy (1)
Clinical research (502)
Collaboration (5)
Compensation (1)
COVID-19 (22)
CRISPR (2)
C-suite (11)
Data (29)
Diabetes (1)
Diagnostics (11)
Diversity, equity & inclusion (5)
Drug discovery (2)
Drug pricing (2)
Duchenne muscular dystrophy (3)
Earnings (375)
Employer branding (1)
Employer resources (6)
Events (495)
Executive appointments (9)
FDA (74)
Funding (8)
Gene editing (3)
Gene therapy (5)
GLP-1 (10)
Government (27)
Guidances (4)
Healthcare (34)
Huntington's disease (2)
IgA nephropathy (1)
Immunology and inflammation (1)
Indications (1)
Infectious disease (23)
Inflation Reduction Act (2)
Interviews (1)
IPO (54)
Job creations (23)
Job search strategy (4)
JPM (3)
Layoffs (6)
Leadership (1)
Legal (60)
Liver cancer (1)
Lung cancer (1)
Lymphoma (1)
Manufacturing (3)
MASH (1)
Medical device (14)
Medtech (14)
Mergers & acquisitions (55)
Metabolic disorders (6)
Neurodegenerative disease (4)
Neuroscience (14)
NextGen: Class of 2026 (21)
Non-profit (8)
Obesity (3)
Opinion (15)
Pain (1)
Parkinson's disease (1)
Patents (1)
Patient recruitment (1)
People (387)
Phase 1 (185)
Phase 2 (162)
Phase 3 (236)
Pipeline (30)
Policy (3)
Postmarket research (5)
Preclinical (80)
Rare diseases (16)
Real estate (20)
Recruiting (1)
Regulatory (92)
Research institute (6)
RNA editing (1)
Schizophrenia (1)
Series A (4)
Series B (3)
Sickle cell disease (1)
Special edition (2)
Spinal muscular atrophy (1)
Startups (36)
Supply chain (2)
Tariffs (1)
The Weekly (3)
Vaccines (10)
Venture capital (2)
Weight loss (2)
Date
Last 7 days (1)
Last 30 days (11)
Last 365 days (138)
2026 (15)
2025 (138)
2024 (129)
2023 (135)
2022 (223)
2021 (209)
2020 (201)
2019 (152)
2018 (184)
2017 (131)
2016 (112)
2015 (126)
2014 (139)
2013 (100)
2012 (108)
2011 (113)
2010 (159)
Location
Africa (6)
Asia (69)
Australia (10)
California (31)
Canada (7)
China (3)
Europe (207)
Japan (1)
Massachusetts (88)
New Hampshire (3)
New Jersey (2)
New York (10)
North Carolina (1)
North Dakota (1)
Northern California (29)
Pennsylvania (6)
South America (5)
Southern California (2)
Texas (1)
United States (143)
Wisconsin (1)
2,837 Results for "alnylam pharmaceuticals.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
January 12, 2026
·
11 min read
Earnings
‘Very Impressive’ Amvuttra ATTR-CM Sales Send Alnylam Soaring
In its first commercial quarter for ATTR-cardiomyopathy, Alnylam’s Amvuttra reached roughly 1,400 patients and made more than $490 million.
August 1, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
January 29, 2026
·
1 min read
Press Releases
Alnylam Pharmaceuticals Announces Changes to Board of Directors
December 3, 2025
·
7 min read
Press Releases
Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
·
2 min read
Cardiovascular disease
Alnylam’s Amvuttra Approved as First RNAi Silencer for Rare Type of Cardiomyopathy
The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin stabilizers for transthyretin amyloid cardiomyopathy.
March 20, 2025
·
8 min read
·
Heather McKenzie
Press Releases
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
December 12, 2025
·
4 min read
Press Releases
Alnylam to Webcast Presentations at Upcoming November 2025 Investor Conferences
November 5, 2025
·
1 min read
Cardiovascular disease
Pfizer Mounts Defense of Cardiac Blockbuster as Alnylam, BridgeBio Enter Market
Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.
April 22, 2025
·
5 min read
·
Nick Paul Taylor
Deals
Roche Keeps the Deals Coming With up to $1.7B SangeneBio RNAi Pact
The alliance will add to Roche’s RNAi efforts, which include the hypertension candidate zilbesiran, partnered with Alnylam under a July 2023 agreement.
February 3, 2026
·
1 min read
·
Tristan Manalac
1 of 284
Next
